Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Fabino Enterprises's PB Ratio or its related term are showing as below:
BOM:543444'
s PB Ratio Range Over the Past 10 Years
Min: 0.65 Med: 1.4 Max: 6.83
Current: 1.17
During the past 8 years, Fabino Enterprises's highest PB Ratio was 6.83. The lowest was 0.65. And the median was 1.40.
BOM:543444's PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.94
vs BOM:543444: 1.17
During the past 12 months, Fabino Enterprises's average Book Value Per Share Growth Rate was -13.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.10% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Fabino Enterprises was 89.40% per year. The lowest was -3.90% per year. And the median was 47.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fabino Enterprises PB Ratio Related Terms
Fabino Enterprises PB Ratio Historical Data
* Premium members only.
The historical data trend for Fabino Enterprises's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fabino Enterprises's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fabino Enterprises PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fabino Enterprises's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fabino Enterprises's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fabino Enterprises (BOM:543444) has a PB Ratio of 1.17 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fabino Enterprises and its competitors. This is 16% below median its historical median of 1.40. Over the past decade, Fabino Enterprises' PB Ratio has ranged from 0.65 to 6.83.
Is Fabino Enterprises' PB Ratio too high?
Fabino Enterprises' current PB Ratio of 1.17 is 16% below median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 6.83. The Drug Manufacturers industry median PB Ratio is 1.94. Fabino Enterprises' value of 1.17 is 39.7% below this industry median. Overall, Fabino Enterprises has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Fabino Enterprises' PB Ratio compare to ZTS and UTHR?
Fabino Enterprises' PB Ratio of 1.17 can be compared against companies in the Drug Manufacturers industry. The industry median PB Ratio is 1.94. Fabino Enterprises' value of 1.17 is 39.7% below this benchmark. Historically, Fabino Enterprises' own PB Ratio has ranged from 0.65 to 6.83 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.94, Fabino Enterprises has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.94, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fabino Enterprises's current PB Ratio of 1.17 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fabino Enterprises and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fabino Enterprises's current PB Ratio is 1.17, which is 16% below median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fabino Enterprises stock overvalued right now?
Fabino Enterprises (BOM:543444) has a current PB Ratio of 1.17. The stock's GF Value™ is ₹37.57, compared to a current price of ₹20.31 — trading 45.9% below its estimated fair value. The current PB Ratio is 1.17, which is 16% below median its 10-year median of 1.40 and 39.7% below the Drug Manufacturers industry median of 1.94. Fabino Enterprises' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fabino Enterprises (BOM:543444), the current PB Ratio is 1.17 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fabino Enterprises (BOM:543444) Overvalued in 2026?
Based on GuruFocus' analysis, Fabino Enterprises stock appears to be undervalued.
The current stock price of ₹20.31 is trading 45.9% below its estimated GF Value™ of ₹37.57.
Key valuation signals for BOM:543444:
PB Ratio: 1.17 (16% below median its 10-year median of 1.40)
GF Value™: ₹37.57 vs. price of ₹20.31 (45.9% below fair value)
Industry Position: 39.7% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:543444 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fabino Enterprises Ltd formerly known as Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.
68GF Score
Get the complete analysis for BOM:543444
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543444 has been successfully added to your 
